SCHEMBL4480591

SCHEMBL4480591

COc1ccc(-c2cc(O)c3cc(OC)ccc3n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 6/20 0.64
KDM4E B2RXH2 6/20 0.61
SMN1; SMN2 Q16637 3/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
MAPT P10636 4/20 0.56
ALDH1A1 P00352 3/20 0.56
LMNA P02545 2/20 0.56
HPGD P15428 2/20 0.56
ACACA Q13085 1/20 0.56
HTT P42858 1/20 0.56
AURKA O14965 1/20 0.53
AURKB Q96GD4 1/20 0.53
ESR1 P03372 1/20 0.52
ESR2 Q92731 1/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10610678 0.92 KDM4E (0.71) PLA2G2AKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL12732312 0.88 KDM4E (0.58) PLA2G2AKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL10612092 0.86 MAPT (0.71) KDM4ESMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL4480750 0.84 KDM4E (0.53) PLA2G2AKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL4492769 0.83 KDM4E (0.49) PLA2G2AKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL15998647 0.82 KDM4E (0.54) PLA2G2AKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL743975 0.82 KDM4E (0.72) PLA2G2AKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL18296635 0.82 RAB9A (0.51) PLA2G2AKDM4EMEN1KMT2AMAPT
SCHEMBL4496204 0.81 KDM4E (0.65) PLA2G2AKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL29636809 0.81 KDM4E (0.65) PLA2G2AKDM4ESMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632845-B2 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents WYETH (US) 2009-12-15 US disclosed
US-20060217399-A1 Phenyl quinolines and their use as estrogenic agents WYETH (US) 2006-09-28 US disclosed
US-7084276-B2 Phenyl quinolines and their use as estrogenic agents WYETH (US) 2006-08-01 US disclosed
EP-1628961-A1 PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS Wyeth (US) 2006-03-01 EP disclosed
US-20050009784-A1 Phenyl quinolines and their use as estrogenic agents WYETH 2005-01-13 US disclosed
WO-2004103973-A1 PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS WYETH (US) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009784-A1 Phenyl quinolines and their use as estrogenic agents ESR1, GPER1, ESR2 PLA2G2A 2311/4885KDM4E 638/4885SMN1; SMN2 4647/4885
US-20060217399-A1 Phenyl quinolines and their use as estrogenic agents ESR1, GPER1, ESR2 PLA2G2A 2311/4885KDM4E 638/4885SMN1; SMN2 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.